I'd go back to the points I made earlier. My list would be a well-funded COVAX; transparency in vaccine pricing; properly negotiated subsidy contracts, so that when governments subsidize research there is some give-and-take, which did not happen this time; opacity in contracting, vaccine hoarding and vaccine diplomacy; and finally, like the CGIAR, an international system that creates IP. If we had all of these things, we wouldn't need the IP waiver. We don't have any of them, so let's move on some of them.
I do find it interesting that on the one hand we're saying with reference to the IP waiver that IP isn't that important and it wouldn't make a lot of difference, but we're still fighting tooth and nail against it. The fact that so many people who actually know this are also for the IP waiver, and these are some very eminent global leaders who actually dealt with the industry, leads me to think that there might be something here. I'm not the expert on this, but it strikes me that there are six or seven things that we should be doing here, and we're not getting any of them right. The IP waiver is one of them.